UPDATE: Appeals Court Decides Isolated DNA Patentable, Myriad's Analytical Method Claims Not
August 03, 2011
UPDATE: Appeals Court Decides Isolated DNA Patentable, Myriad's Analytical Method Claims Not
The appeals court decided that isolated gene sequences do not occur naturally and are therefore patentable, but invalidated Myriad's method claims that describe "comparing" or "analyzing" DNA sequences, deeming them abstract, mental steps.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- At Appeals Hearing, Myriad Outlines Stance on BRCA IP Rights for Whole-Genome Sequencing
April 6, 2011 / Pharmacogenomics Reporter - Appeals Court Says Prometheus Meets Machine/Transformation Test; Impact on Gene Patents Uncertain
December 22, 2010 / Pharmacogenomics Reporter - Federal Circuit Judges Considered USPTO Policy, Industry Impact in Ruling on Myriad's Gene Patents
August 22, 2012 / Pharmacogenomics Reporter - US DoJ Argues Against Patenting Isolated Genes, But USPTO Will Maintain Status Quo
November 3, 2010 / Pharmacogenomics Reporter - Game On: Court Ruling on Myriad Patents to Kick off Protracted Legal Battle Over DNA Patentability
March 31, 2010 / Pharmacogenomics Reporter